When it comes to the ins and outs of investment, Paul Mampilly is the man to consult. He is the senior chief editor of Extreme Fortunes, Profits Unlimited, and True Momentum at the Banyan Hill publisher. He is the founder of the Profit Unlimited newsletter that argues and guides its subscribers on the various stocks that are on their way to shooting higher. In addition, he also writes the Bayan Hill publisher weekly column. The guide he offers to his subscribers helps them make informed decisions when it comes to investment companies. One such decision is the greatest medical breakthrough in all of history. Visit Bloomberg to know more about Paul Mampilly.
According to Paul Mampilly, the breakthrough is more important than any drug, vaccine, medical device or the three combined. The breakthrough will change the approach people take when tackling a disease. A 1.5 million mid-western company is on the verge of creating the greatest history when it comes to medical discoveries. The company is experimenting with precision medicine. What exactly is precision medicine? Precision medicine is looking at a person’s DNA and coming up with a medication that fits a person’s DNA structure. The medication would then be custom made to fit the individual and prevent the disease from developing.
If precision medicine is possible then chronic diseases like Diabetes, Arthritis, heart disease among others could be wiped out simply by looking directly into a person’s DNA. The mid-western company was founded in the 1990s. The CEO of the company has a 25-year experience in biotechnology research. He uses his experience and contacts to bring in the top minds in the biotechnology world to work at his facility and help develop the precision medicine. Apart from precision medicine, the company is also leading in the molecular diagnostics DNA industry. By using molecular diagnostics DNA, they are able to assess whether a person will develop a disease and determine the best medical response to the disease. Follow Paul on Facebook.
The company is known as Myriad Genetics. From Paul’s teaser on the future rise of Myriad’s stock, the stock has continued to rise and changed the past state of the company’s stock price. By the time Paul Mampilly recommended Myriad Genetics stock to his subscribers, the stock price was in a range of $24-25. With the good stock reports the company has been receiving lately, the stock prices continue to increase from $1.5 billion to $2.2 billion. The rise makes the company more promising. Read more: http://www.talkmarkets.com/contributor/Paul-Mampilly/